Ra pharmaceuticals, inc. (RARX)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15
Revenue

-

3,000

-

-

-

-

-

-

-

-

-

-

0

0

3,044

1,884

1,096

Operating expenses:
Research and development

26,202

23,244

17,914

15,282

15,357

13,375

12,305

13,412

12,645

13,130

10,464

9,012

9,387

7,079

6,505

4,957

4,027

General and administrative

11,625

5,972

4,933

4,807

3,802

3,504

3,821

3,312

2,677

2,284

2,348

2,469

1,606

1,042

1,085

1,291

539

Total operating expenses

37,827

29,216

22,847

20,089

19,159

16,879

16,126

16,724

15,322

15,414

12,812

11,481

10,993

8,121

7,590

6,248

4,566

Loss from operations

-37,827

-26,216

-22,847

-20,089

-16,659

-16,879

-16,126

-16,724

-15,322

-15,414

-12,812

-11,481

-10,993

-8,121

-4,546

-4,364

-3,470

Other income (expense):
Interest expense with related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

Loss on debt extinguishment with related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-602

Other expense, net

-3,264

1,241

950

1,050

-1,019

375

380

226

-483

139

149

121

-22

7

-260

-692

154

Total other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-462

Net loss

-36,777

-24,975

-21,897

-19,039

-16,195

-16,504

-15,746

-16,498

-15,141

-15,275

-12,663

-11,360

-10,888

-8,114

-4,806

-5,056

-3,932

Gain on extinguishment of redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,673

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,259

Net loss per share - basic and diluted (in dollars per share)

-0.79

-0.55

-0.52

-0.45

-0.45

-0.51

-0.49

-0.61

-0.67

-0.68

-0.56

-0.50

25.56

-14.22

-8.90

-9.42

-4.57

Weighted average number of common shares outstanding - basic and diluted (in shares)

47,218

45,766

42,294

42,174

34,270

32,349

32,307

27,242

22,626

22,614

22,575

22,549

14,892

571

540

537

494